RIP kinase Inhibitor

RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (K_d=9.2 nM; IC₅₀=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC₅₀=17-30 nM). Anti-inflammatory activity.

PB830 (compound 41) is a potent receptor interacting protein 1 kinase (RIP1) Inhibitor with an IC₅₀ of <100 nM for human RIP1. PB830 has an EC₅₀ of 1-100 nM in the cell necrosis assay.

LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC₅₀ values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis.

Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC₅₀ of 2.6 μM, K_i of 0.46 μM.

RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC₅₀ values of 1.6 and 2.9 nM, respectively.

RIPK1-IN-28 (compound 13) is an orally active RIPK1 inhibitor. RIPK1-IN-28 inhibits human I2.1 and Hepa1‐6 cells with IC₅₀s of 0.4 and 1.2 nM, respectively.

Ripk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ripk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

RIPK1-ligand-2 is a RIPK1 inhibitor. RIPK1-ligand-2 can be used for synthesis of PROTAC RIPK1 Degrader-1 (HY-175370).

UH15-38 TFA is a potent RIPK3 inhibitor with an IC₅₀ value of 20 nM. UH15-38 TFA blocks IAV (influenza A virus)-activated necroptosis. UH15-38 TFA dampens IAV-induced lung injury.

RIP1 kinase inhibitor 8 (Compound 77) is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC₅₀ of 20 nM. RIP1 kinase inhibitor 8 prevents necrotic cell death. RIP1 kinase inhibitor 8 shows a favorable pharmacokinetic profile in multiple species.

RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC₅₀ value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells.

RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC₅₀ of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer.

NOD1-RIPK2-IN-1 (Compound 37) is a NOD1-RIPK2 signaling pathway inhibitor with IC₅₀ values of 42 nM and 1.52 nM for NOD1 and RIPK2, respectively. NOD1-RIPK2-IN-1 reduces the secretion of the pro-inflammatory cytokine IL-8 and can be used in the research of inflammation and immune-related diseases.

RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC₅₀ values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC₅₀ value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay.

SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a K_d of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC₅₀=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects.

TNF-α-IN-19 is an inhibitor of TNFα that can block the interaction between TNFαRI, TRADD, and RIP1, the EC₅₀ values for TNFα, IL-1β, and IL-1β/TNFα are 2.451, 3.792 and 1.54 μM, respectively. TNF-α-IN-19 only inhibits the degradation of IκBα when cells are stimulated by TNFα and not by IL-1β.

RIPK3-IN-6 (compound 1) is a type I RIPK3 inhibitor with poor selectivity for the RIPK family, especially for RIPK2 activity.

RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury.

RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pK_i of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC₅₀ of 7.2.

Ripk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ripk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.